← Back to Patent Explorer
US4579730A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical compositions containing insulin

Assignee: Hadassah Medical Organization
•
Filing: 1984-05-09
•
Granted: 1986-04-01
•
Expires: 2004-05-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention provides a pharmaceutical composition for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof, the bile acid being selected from the group consisting of cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3 beta -hydroxy-12-ketocholic acid, 12 alpha -3 beta -dihydrocholic acid, and ursodesoxycholic acid, and a protease inhibitor, the composition being provided with an enterocoating to assure passage through the stomach and release in the intestine.

Inventors

  • 👤 Miriam Kidron
  • 👤 Ehud Ziv
  • 👤 Hanoch Bar-On
  • 👤 Amiram Eldor

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 17:33
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/28; A61K38/55; A61K9/00; A61K9/20; A61K9/2004; A61K9/2013; A61K9/2068; A61K9/28; A61K9/2806; A61K9/2833; A61K9/284; A61K9/2846

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 104 words
A pharmaceutical composition for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof which does not cause the damage to the cells of the intestinal wall caused by deoxycholic acid, said bile acid being selected fom the group consisting of sodium cholate cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3β-monohydroxychloric acid, lithocholic acid, 3α-hydroxy-12-ketocholic acid, 3β-hydroxy-12-ketocholic acid, 12α-3β-dihydrocholic acid, and ursodesqxycholic acid, and a carefully screened and tested dosage amount of protease inhibitor, said composition being provided with an enterocoating to assure passage through the stomach and release of insulin in the intestine.
Claim 2
Dependent Claim 104 words
A pharmaceutical composition for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof which does not cause the damage to the cells of the intestinal wall caused by deoxycholic acid, said bile acid being selected fom the group consisting of sodium cholate cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3β-monohydroxychloric acid, lithocholic acid, 3α-hydroxy-12-ketocholic acid, 3β-hydroxy-12-ketocholic acid, 12α-3β-dihydrocholic acid, and ursodesqxycholic acid, and a carefully screened and tested dosage amount of protease inhibitor, said composition being provided with an enterocoating to assure passage through the stomach and release of insulin in the intestine.
Claim 3
Dependent Claim 42 words
A pharmaceutial composition for the oral administration of insulin according to claim 1 wherein said protease inhibitor is selected from the group consisting of sodium cholate aprotinin, A 2 -macroglobulin, antithrombin III and trypsin inhibitor from soy bean or chicken egg white.
Claim 4
Dependent Claim 25 words
A pharmaceutical composition for the oral administration of insulin according to claim 1 comprising sodium cholate as both the bile acid and the protease inhibitor.
Claim 5
Dependent Claim 33 words
A pharmaceutical composition for the oral administration of insulin according to claim 1 wherein the components of said composition are microencapsulated and enterocoated to provide for timed release of ingredients in the intestine.

References Cited (Backward Citations)

JPS5257313A Cited
DE2640707A1 Cited
FR2515960A1 Cited
EP0127535A2 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-03-31 1989-09-30 1990-04-01 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-03-31 1993-09-30 1994-04-01 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-03-31 1997-09-30 1998-04-01 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag